Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Penny L Moore

Showing results (81-90 of 215) with videos related to

Pageof 22
Sort By:
Virology|April 16, 2010
Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and ScytovirinKabamba B Alexandre, Elin S Gray, Bronwen E Lambson, et al.
Clinical Immunology (Orlando, Fla.)|July 19, 2024
Aberrant innate immune profile associated with COVID-19 mortality in Pretoria, South AfricaMieke A van der Mescht, Zelda de Beer, Helen C Steel, et al.
The Lancet. Infectious Diseases|June 8, 2023
Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in AfricaBavesh D Kana, Patrick Arbuthnot, Benjamin K Botwe, et al.
Journal of Virology|April 15, 2018
Correction for Anthony et al., "Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope"Colin Anthony, Talita York, Valerie Bekker, et al.
Journal of Virology|July 7, 2017
Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing EpitopeColin Anthony, Talita York, Valerie Bekker, et al.
Viruses|February 26, 2025
Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV ChallengeGerald K Chege, Rosamund E Chapman, Alana T Keyser, et al.
Journal of Virology|March 11, 2011
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infectionElin S Gray, Maphuti C Madiga, Tandile Hermanus, et al.
Plos Pathogens|December 17, 2019
IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibodySimone I Richardson, Bronwen E Lambson, Andrew R Crowley, et al.
Plos Pathogens|September 2, 2022
Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodiesCathrine Scheepers, Prudence Kgagudi, Nonkululeko Mzindle, et al.
Scientific Reports|June 10, 2024
Evaluating the antibody response elicited by diverse HIV envelope immunogens in the African green monkey (Vervet) modelThandeka Moyo-Gwete, Frances Ayres, Nonkululeko B Mzindle, et al.
Pageof 22

Showing results (81-90 of 215) with videos related to

Sort By:
Pageof 22
Virology|April 16, 2010
Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and ScytovirinKabamba B Alexandre, Elin S Gray, Bronwen E Lambson, et al.
Clinical Immunology (Orlando, Fla.)|July 19, 2024
Aberrant innate immune profile associated with COVID-19 mortality in Pretoria, South AfricaMieke A van der Mescht, Zelda de Beer, Helen C Steel, et al.
The Lancet. Infectious Diseases|June 8, 2023
Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in AfricaBavesh D Kana, Patrick Arbuthnot, Benjamin K Botwe, et al.
Journal of Virology|April 15, 2018
Correction for Anthony et al., "Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope"Colin Anthony, Talita York, Valerie Bekker, et al.
Journal of Virology|July 7, 2017
Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing EpitopeColin Anthony, Talita York, Valerie Bekker, et al.
Viruses|February 26, 2025
Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV ChallengeGerald K Chege, Rosamund E Chapman, Alana T Keyser, et al.
Journal of Virology|March 11, 2011
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infectionElin S Gray, Maphuti C Madiga, Tandile Hermanus, et al.
Plos Pathogens|December 17, 2019
IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibodySimone I Richardson, Bronwen E Lambson, Andrew R Crowley, et al.
Plos Pathogens|September 2, 2022
Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodiesCathrine Scheepers, Prudence Kgagudi, Nonkululeko Mzindle, et al.
Scientific Reports|June 10, 2024
Evaluating the antibody response elicited by diverse HIV envelope immunogens in the African green monkey (Vervet) modelThandeka Moyo-Gwete, Frances Ayres, Nonkululeko B Mzindle, et al.
Pageof 22